bax,
I don't recall if you said that you are a new investor or just new as a Medify investor. Regardless, I applaud your take charge attitude in calling Trevor, Oracle and checking other sources for verification of Medify as a company.
It is also refreshing to know that you understand that, like any company's management, Medify cannot divulge priviledged information to any single investor. Rather, news is released within a reasonable time after event occurrence for all to see. It still amazes me that numerous people on these boards seem to believe that the company has an obligation to keep us abreast of what is happening within the company when in fact that would be illegal. All one has to do is read the PR's to know that they are involved in a great deal of very promising things. Their partners alone speak volumes about where this company is going.
As a reminder, the Cheshire deal that is being piloted and nearing completion as early as late July will be worth approximately $40m in revenues. This deal alone will place a value of about $3 per share on the company based on the current outstanding share count and using a conservative 30% net revenue figure with a forward multiple of 20.
I have a lot of confidence in Medify's ability to deliver and see them as a very succssful company once on a higher exchange.
cheers
Market Data 
Markets 
AI
